Standard of Care: Balancing Fast and Slow Rhythms
At a Glance
Hereditary conduction disease can combine fast atrial rhythms such as AFib with dangerous slowing or blocking of the heart’s electrical signals. Treatment balances both problems using a pacemaker or ICD when needed, plus medicines, ablation, and stroke prevention.
Treating Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease is often described as a “balancing act.” Your care team must manage two opposite problems: a heart that sometimes beats too fast in the top chambers and a “wiring” system that is too slow in the bottom chambers [1].
Because many treatments for a fast heart can accidentally make a slow heart even slower, doctors often follow an individualized decision pathway to keep you safe.
The Foundation: Managing the “Slow” (Conduction Disease)
The first priority is ensuring your heart maintains a safe, reliable beat. Because the “infra-Hisian” part of your heart is deep in the electrical system, signals that get blocked there are very unlikely to be fixed by medicine [2].
- Pacemakers: This is a primary treatment for symptomatic bradycardia or block on the “slow” side of your condition [1]. A pacemaker acts as a safety net, monitoring your heart and “stepping in” with a small electrical pulse if your natural signal is too slow or blocked [3].
- When is it time?: Doctors look for specific triggers to recommend a pacemaker. These include a history of fainting (syncope), a “complete block” where no signals reach the bottom chambers, or a high-risk finding on an EP study, such as an HV interval of 70 milliseconds or more depending on guidelines and clinical context [4][5].
- A Balancing Act: If you have fast rhythms that need treatment, your doctor may recommend a pacemaker if you need rate-slowing drugs that could cause complete heart block if the wiring is already weak [2][6].
The Balancing Act: Managing the “Fast” (Atrial Rhythms)
With your heart rate secured, your doctors can more aggressively treat the fast atrial rhythms like AFib or flutter. (Note a pacemaker does not cure AFib or prevent strokes).
- Antiarrhythmic Drugs: These medications help the heart maintain a steady rhythm. However, they must be chosen carefully; for example, some drugs (like flecainide) must be used with specialist oversight, as they can worsen conduction delays in specific SCN5A phenotypes or structural disease [7].
- Catheter Ablation: This is a procedure where a doctor uses heat or cold to “neutralize” the tiny spots in the heart causing the fast rhythms [8]. It can be very effective at reducing symptoms and may be recommended if medications aren’t working or are causing too many side effects [9][10].
- Anticoagulation (Blood Thinners): If you have atrial fibrillation, your blood can “pool” in the top chambers, increasing the risk of a stroke [11]. Your doctor will calculate your stroke risk and bleeding risk and may prescribe blood thinners to protect you, regardless of whether you feel the AFib or not [11][12].
When an ICD is Necessary
For most patients, a standard pacemaker is sufficient. However, for those with certain “high-risk” factors, an Implantable Cardioverter Defibrillator (ICD) may be used instead [1].
An ICD does everything a pacemaker does, but it also has the ability to deliver a life-saving shock if the bottom chambers of the heart develop a dangerous, rapid rhythm (Ventricular Tachycardia or Fibrillation) [13]. An ICD is more likely to be recommended if:
- You have survived a cardiac arrest or have a history of dangerous ventricular rhythms [14].
- Your heart muscle has become weak or enlarged (often seen in LMNA or some PRKAG2 cases) [15][16].
- Advanced imaging (MRI) shows significant scarring (fibrosis) in the heart muscle [17].
- You have a high-risk LMNA mutation, where specific risk models suggest elevated risk based on validated models, acknowledging that thresholds differ among guidelines [18].
Your treatment plan is highly individualized. It depends not just on your symptoms, but on your specific genetic mutation and the data from your latest heart tests.
Common questions in this guide
Why might I need a pacemaker for hereditary conduction disease?
Does a pacemaker cure AFib or prevent a stroke?
When would an ICD be chosen instead of a standard pacemaker?
How are AFib and flutter treated when conduction disease is present?
Will I need a blood thinner if I have AFib?
How do genetic test results affect treatment for this condition?
One line in your results can change your plan.
An EP study's HV interval can be one trigger for a pacemaker, depending on guidelines and clinical context. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Current Topics of Progressive Cardiac Conduction Disease.
Sumitomo N, Mori H, Kumamoto T, et al.
Journal of arrhythmia 2026; (42(3)):e70383 doi:10.1002/joa3.70383.
PMID: 42368294 - 2
Atypical Wenckebach AV Block in the Infra-Hisian Region: Clinical Implications and Management.
Kaushik A, Jeewooth A, Jaswal A, et al.
The American journal of case reports 2024; (25()):e946186 doi:10.12659/AJCR.946186.
PMID: 39702956 - 3
Molecular and genetic insights into progressive cardiac conduction disease.
Asatryan B, Medeiros-Domingo A
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2019; (21(8)):1145-1158 doi:10.1093/europace/euz109.
PMID: 31087102 - 4
Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1.
Clementy N, Labombarda F, Grolleau F, et al.
JAMA cardiology 2025; (10(11)):1121-1129 doi:10.1001/jamacardio.2025.3055.
PMID: 40991257 - 5
Incidence and management of atrioventricular conduction disorders in new-onset left bundle branch block after TAVI: A prospective multicenter study.
Massoullié G, Ploux S, Souteyrand G, et al.
Heart rhythm 2023; (20(5)):699-706 doi:10.1016/j.hrthm.2023.01.013.
PMID: 36646235 - 6
A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction Disease in Patients With Myotonic Dystrophy Type 1.
Creta A, Providência R, Gossios T, et al.
JACC. Clinical electrophysiology 2021; (7(8)):1038-1048 doi:10.1016/j.jacep.2021.01.017.
PMID: 33812832 - 7
Biophysical mechanisms of myocardium sodium channelopathies.
Zaytseva AK, Kulichik OE, Kostareva AA, Zhorov BS
Pflugers Archiv : European journal of physiology 2024; (476(5)):735-753 doi:10.1007/s00424-024-02930-3.
PMID: 38424322 - 8
Catheter ablation for atrial fibrillation: current indications and evolving technologies.
Parameswaran R, Al-Kaisey AM, Kalman JM
Nature reviews. Cardiology 2021; (18(3)):210-225 doi:10.1038/s41569-020-00451-x.
PMID: 33051613 - 9
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation.
Andrade JG, Wells GA, Deyell MW, et al.
The New England journal of medicine 2021; (384(4)):305-315 doi:10.1056/NEJMoa2029980.
PMID: 33197159 - 10
Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.
Mark DB, Anstrom KJ, Sheng S, et al.
JAMA 2019; (321(13)):1275-1285 doi:10.1001/jama.2019.0692.
PMID: 30874716 - 11
Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.
Johner N, Gencer B
European journal of clinical investigation 2026; (56(5)):e70224 doi:10.1111/eci.70224.
PMID: 42148709 - 12
Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process.
Chang TY, Lip GYH, Chen SA, Chao TF
The Canadian journal of cardiology 2019; (35(5)):611-618 doi:10.1016/j.cjca.2019.01.018.
PMID: 31030863 - 13
Ventricular Fibrillation in PRKAG2 Cardiomyopathy: A Genetic Arrhythmia Substrate Beyond Wolff-Parkinson-White.
Visch J, Hopman LHGA, Holtus D, et al.
JACC. Case reports 2026; 110634 doi:10.1016/j.jaccas.2026.110634.
PMID: 42853170 - 14
Implantable cardioverter-defibrillator implantation for primary and secondary prevention: indications and outcomes.
Pick JM, Batra AS
Cardiology in the young 2017; (27(S1)):S126-S131 doi:10.1017/S1047951116002365.
PMID: 28084973 - 15
Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis.
Lopez-Sainz A, Dominguez F, Lopes LR, et al.
Journal of the American College of Cardiology 2020; (76(2)):186-197 doi:10.1016/j.jacc.2020.05.029.
PMID: 32646569 - 16
Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy.
Akhtar M, Elliott PM
Current cardiology reports 2019; (21(12)):155 doi:10.1007/s11886-019-1236-3.
PMID: 31768884 - 17
Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study.
Peretto G, Barison A, Forleo C, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2020; (22(12)):1864-1872 doi:10.1093/europace/euaa171.
PMID: 32995851 - 18
Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies.
Wahbi K, Ben Yaou R, Gandjbakhch E, et al.
Circulation 2019; (140(4)):293-302 doi:10.1161/CIRCULATIONAHA.118.039410.
PMID: 31155932
This page explains treatment choices for hereditary atrial rhythm and infra-Hisian conduction disease for informational purposes only and does not constitute medical advice. An electrophysiologist should interpret your ECG, genetic results, and individual treatment risks.